TRexBio priced an IPO at $117 million for Tregs, reflecting continued investor appetite for immunology-focused platforms. The company’s offering comes alongside other recent Nasdaq debut activity tied to hypertension, underscoring that market risk tolerance still varies by therapeutic area and story. Near-term attention will turn to how IPO proceeds translate into clinical catalysts and whether early risk profiles match investor expectations for Treg-expansion strategies.